Thrombophilia Screen: Who & When? MRCP Part 1

TL;DR

For MRCP Part 1, mastering who to test and when to test for thrombophilia is more important than memorising every disorder. Thrombophilia screening is indicated in selected patients—such as young individuals with unprovoked or recurrent VTE—but should not be done routinely. Testing must be timed correctly, avoiding the acute phase and anticoagulation, to prevent misleading results.

Why this matters

Thrombophilia screening is a classic MRCP Part 1 topic because it tests clinical judgement rather than rote learning. Candidates are expected to differentiate appropriate vs inappropriate testing, recognise timing pitfalls, and understand when results actually influence management.

Examiners frequently construct questions around subtle decision-making—particularly scenarios where testing is not indicated. This makes the topic disproportionately high-yield despite its seemingly narrow scope.

For a structured overview of the exam, visit the MRCP Part 1 overview. You can reinforce concepts using Free MRCP MCQs.

What is a thrombophilia screen?

A thrombophilia screen evaluates inherited and acquired predispositions to thrombosis. It typically includes:

• Inherited conditions

  • Factor V Leiden mutation

  • Prothrombin G20210A mutation

  • Protein C deficiency

  • Protein S deficiency

  • Antithrombin deficiency

• Acquired condition

  • Antiphospholipid syndrome (APS)

💡 Exam insight: APS is the only thrombophilia strongly associated with arterial thrombosis, making it a frequent exam focus.

WHO should be tested? (High-yield indications)

Thrombophilia testing should be targeted, not routine. The following are key indications:

1. Unprovoked VTE under age 50

2. Recurrent venous thromboembolism

3. Thrombosis at unusual sites (e.g. cerebral venous sinus, portal vein)

4. Strong family history of VTE

5. Recurrent pregnancy loss (suspected APS)

6. Warfarin-induced skin necrosis (suggests protein C deficiency)

7. Neonatal purpura fulminans

8. Selected pregnancy-related VTE cases

💡 Exam trigger phrase: “Young patient with unprovoked DVT” → think thrombophilia testing (but not immediately).

WHO should NOT be tested?

Equally important—and frequently examined:

• Provoked VTE (e.g. surgery, immobilisation, trauma)

• First VTE in older patients (>60 years) without family history

• Patients already requiring lifelong anticoagulation

• Arterial thrombosis without APS suspicion

💡 Core principle: If the result will not change management, testing is unnecessary.

WHEN to test? (Critical timing rules)

Timing is one of the most tested aspects in MRCP Part 1.

Clinical scenario	Test now?	Reason
Acute thrombosis	❌ No	Acute phase lowers protein C/S, antithrombin
On warfarin	❌ No	Reduces protein C/S levels
On heparin	❌ No	Affects antithrombin levels
On DOACs	❌ Avoid	Interferes with assays
≥3 months post-event and off anticoagulation	✅ Yes	Accurate results

💡 Golden rule: Test after anticoagulation is stopped, usually after at least 3 months of treatment and a washout period.

WHAT tests are included? (Top 5 to know)

Focus on these core tests:

1. Factor V Leiden mutation

2. Prothrombin gene mutation

3. Protein C activity

4. Protein S activity

5. Antithrombin III levels

Additionally:

• Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-β2 glycoprotein I)

The 5 most tested subtopics

1. Factor V Leiden

• Most common inherited thrombophilia

• Causes resistance to activated protein C

2. Antiphospholipid syndrome (APS)

• Venous + arterial thrombosis

• Recurrent miscarriages

• Requires persistent antibodies (≥12 weeks apart)

3. Protein C and S deficiency

• Associated with warfarin skin necrosis

• Levels affected by acute illness and warfarin

4. Antithrombin deficiency

• May present with heparin resistance

5. Timing of testing

• A favourite MRCP question theme

• Incorrect timing → false results

Clinical relevance: Does testing change management?

A key exam concept:

• Most patients are managed based on clinical factors, not thrombophilia results

• Duration of anticoagulation depends on provoked vs unprovoked VTE

• Exceptions:

  • APS (may require long-term anticoagulation)

  • Pregnancy (affects prophylaxis decisions)

💡 Exam trap: Overestimating the impact of thrombophilia results on management.

High-yield summary (Exam-ready list)

• Do not screen all VTE patients

• Test young patients with unprovoked or recurrent VTE

• Avoid testing during acute thrombosis

• Avoid testing while on anticoagulation

• APS is the only thrombophilia linked to arterial thrombosis

• Results rarely change management

Practical examples / mini-cases

MCQ

A 34-year-old man presents with his first unprovoked deep vein thrombosis. He is started on rivaroxaban. What is the most appropriate next step regarding thrombophilia testing?

A. Perform thrombophilia screen immediatelyB. Test while on rivaroxabanC. Test after completion of anticoagulation and washoutD. Do not testE. Test only for Factor V Leiden

Answer: C. Test after completion of anticoagulation and washout

Explanation:

• Indication present (young, unprovoked VTE)

• DOACs interfere with assays

• Testing should be delayed until anticoagulation is stopped

Common pitfalls (5 bullets)

• Testing during acute thrombosis → false low protein levels

• Ignoring DOAC interference with assays

• Screening provoked VTE unnecessarily

• Assuming all thrombophilias affect arterial risk

• Believing results always change management

Practical study-tip checklist

• ✔ Learn who to test vs who not to test

• ✔ Memorise timing rules (very high yield)

• ✔ Focus on the top 5 thrombophilias

• ✔ Practise MCQs regularly

• ✔ Link knowledge to clinical decision-making

Reinforce your preparation using Free MRCP MCQs and simulate exam conditions with a Start a mock test.

Cross-link suggestion: Pair this topic with anticoagulation strategies and VTE management for integrated revision.

FAQs

1. Should all patients with DVT undergo thrombophilia screening?

No. Testing is reserved for selected cases such as young patients with unprovoked or recurrent VTE. Routine screening does not influence management.

2. When is thrombophilia testing most accurate?

Testing should be performed after anticoagulation is stopped and outside the acute phase—typically several weeks after completing treatment.

3. Does thrombophilia affect anticoagulation duration?

Usually no. Duration is based on clinical risk factors, although APS may influence long-term treatment decisions.

4. Which thrombophilia causes arterial thrombosis?

Antiphospholipid syndrome is the key thrombophilia associated with arterial as well as venous thrombosis.

5. Why should testing be avoided during anticoagulation?

Anticoagulants (especially warfarin and DOACs) alter protein levels and interfere with assays, leading to inaccurate results.

Ready to start?

Prepare systematically with the MRCP Part 1 overview, sharpen your knowledge using Free MRCP MCQs, and assess your readiness with a Start a mock test.

Sources

• MRCP(UK) Part 1 Curriculum: https://www.mrcpuk.org/mrcpuk-examinations/part-1

• NICE Guideline NG158 (VTE): https://www.nice.org.uk/guidance/ng158

• British Society for Haematology Guidelines: https://b-s-h.org.uk/guidelines

• BMJ Best Practice (Thrombophilia): https://bestpractice.bmj.com/topics/en-gb/3000119